New share structure and official listing of new share classes, and total number of voting rights and share capital
Valby, Denmark, June 8, 2022 – H. Lundbeck A/S (Lundbeck) announces that the extraordinary general meeting of Lundbeck held on June 8, 2022 has adopted the proposed share split of Lundbeck’s existing shares. For a summary of all resolutions adopted by the extraordinary general meeting, please see Company Release no. 723.
The approval means that each existing Lundbeck-share with a nominal value of DKK 5 is split into one (1) A share with a nominal value of DKK 1 and four (4) B shares each with a nominal value of DKK 1. Each A share carries ten (10) votes, and each B share carries one (1) vote. Reference is also made to the Listing Document published by Lundbeck on May 20, 2022 which along with documents incorporated therein by reference are published on Lundbeck’s webpage: (https://www.lundbeck.com/global/investors/the-share/new-share-structure).
Application has been made for the A shares and the B shares to be admitted to trading and official listing on Nasdaq Copenhagen. The A shares will be issued in the new ISIN DK0061804697 and will be admitted to trading under the Nasdaq symbol “HLUN A”. The B shares will be issued in the new ISIN DK0061804770 and will be admitted to trading under the Nasdaq symbol “HLUN B”.
The expected schedule for completion of the share split is as follows:
- June 9, 2022: Last day of trading on Nasdaq Copenhagen of Lundbeck’s existing shares in the existing ISIN DK0010287234
- June 10, 2022: First day of trading of the A shares in the new ISIN DK0061804697 under the ticker symbol “HLUN A” and the B shares in the new ISIN DK0061804770 under the ticker symbol “HLUN B”
- June 14, 2022: Delivery of the new A shares and the new B shares to shareholders against cancellation of the existing Lundbeck-shares
In accordance with Section 32 of the Danish Capital Market Act, Lundbeck is required to publish the total number of voting rights and the size of the share capital if changes occur. Following the adoption and implementation of the share split, Lundbeck’s total number of voting rights and total share capital are:
| Number of shares(nominal value of DKK 1 each) | Nominal value(DKK) | Number of votes | |
| A Shares | 199,148,222 | 199,148,222 | 1,991,482,220 |
| B Shares | 796,592,888 | 796,592,888 | 796,592,888 |
| Total | 995,741,110 | 995,741,110 | 2,788,075,108 |
Lundbeck contacts
| Investors: | Media: |
| Palle Holm Olesen | Thomas Mikkel Mortensen |
| Vice President, Investor Relations | Media Relations Lead Corp. Communication |
| [email protected] | THMR@lundbeck.com |
| +45 30 83 24 26 | +45 30 83 30 24 |
IMPORTANT INFORMATION
NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES. NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO ANY PERSON IN ANY JURISDICTION WHERE RELEASE, PUBLICATION OR DISTRIBUTION TO SUCH PERSON IS RESTRICTED BY ANY LAW OR REGULATION APPLICABLE IN SUCH JURISDICTION.
THIS CORPORATE RELEASE IS NOT AN OFFER TO SELL OR INVITATION TO PURCHASE OR SUBSCRIBE FOR, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES.
THE LISTING DOCUMENT HAS BEEN PREPARED SOLELY TO COMPLY WITH LUNDBECK’S OBLIGATIONS PURSUANT TO APPLICABLE DANISH SECURITIES LAW AND REGULATIONS TO COMPLETE THE SHARE SPLIT. THE LISTING DOCUMENT MAY NOT BE RILIED UPON FOR ANY OTHER PURPOSE THAN THE SHARE SPLIT.
About H. Lundbeck A/S
Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best. We are committed to fighting stigma and discrimination against people living with brain diseases and advocating for broader social acceptance of people with brain health conditions. Our research programs tackle some of the most complex challenges in neuroscience, and our pipeline is focused on bringing forward transformative treatments for brain diseases for which there are few, if any therapeutic options.
For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Instagram (h_lundbeck), Twitter at @Lundbeck and via LinkedIn.
Third-party information, legends and Safe Harbor/Forward-Looking Statements
This corporate release may comprise statements from third-parties or reference to third-party information. To the extent information from third-parties follows directly from this document, the company can confirm that the information has been accurately reproduced, but the company cannot give any assurances as to the accuracy of the information or any forward-looking statements in such statements coming into existence. To the extent the company makes any reference to third-party information, including reference to the Lundbeck Foundation’s webpage, such information shall not be considered an integrated part of this corporate release and the company shall have no responsibility for the accuracy of such information. None of the securities referred to herein have been or will be registered under the United States Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state or other jurisdiction in the United States, and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with applicable other securities laws. There will not be any public offering of any of the securities in the United States.
This corporate release contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe", "anticipate", "expect", "estimate", "intend", "plan", "project", "will be", "will continue", "will result", "could", "may", "might", or any variations of such words or other words with similar meanings. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements.
Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Factors that may affect future results include, among others, interest rate and currency exchange rate fluctuations, delay or failure of development projects, production or distribution problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.
The forward-looking statements in this document and oral presentations made on behalf of Lundbeck speak only as at the date of this presentation. Lundbeck does not undertake any obligation to update or revise forward-looking statements in this presentation or oral presentations made on behalf of Lundbeck, nor to confirm such statements to reflect subsequent events or circumstances after the date of the presentation or in relation to actual results, unless otherwise required by applicable law or applicable stock exchange regulations.
